Credit: Original article published here.
Soumya Chakravarty, MD, PhD, FACP, FACR, Senior Director, Strategic Lead, Rheumatology Therapeutic Area at The Janssen Pharmaceutical Companies of Johnson & Johnson, discusses a post-hoc analysis of recent Phase 3 DISCOVER-2 study, which shows that early clinical improvement at eight weeks of joint and skin disease, enthesitis and dactylitis in adult patients with active psoriatic arthritis treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life from year one through year two.
